Novartis AG (NOVN) - Product Pipeline Analysis, 2014 Update

Novartis AG (NOVN) - Product Pipeline Analysis, 2014 Update

Regular price $750.00 Sale

Published on May 16, 2014 - 67 pages

Novartis AG (Novartis) is a healthcare solutions company. It undertakes the discovery, development and commercialization of a wide range of novel and generic products across various therapeutic areas in the human and animal health market. The company's product portfolio includes innovative medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products for the treatment of conditions related to oncology, neurosciences, ophthalmology, respiratory diseases, immunology and infections. The company sells its products in various countries, which are classified by the company into four reportable regions, namely, the US, Americas (except the US), Europe and Rest of the World. Novartis is headquartered in Basel, Switzerland.

The company focuses on strengthening its research and development activities through the launch of new products, expanding its product portfolio. This is evident from the recent approval of Xolair, by the US FDA for the treatment of for chronic idiopathic urticaria and by European Commission as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines. The company also concentrates on inorganic growth such as the acquisition of CoStim Pharmaceuticals Inc., a privately held biotechnology company.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Novartis AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table of Contents

Table of Contents
Table of Contents
List of Tables
List of Figures
Novartis AG Company Snapshot
Novartis AG Company Overview
Key Information
Novartis AG Pipeline Products and Clinical Trials Overview
Novartis AG - Pipeline Analysis Overview
Business Description
Key Facts
Novartis AG - Major Products and Services
Novartis AG Pipeline Products by Development Stage
Novartis AG Clinical Trials by Trial Status
Novartis AG Pipeline Products Overview
CLM041 Product Overview
Diagnostic Test - Cardiac Panel
Diagnostic Test - Cardiac Panel Product Overview
Diagnostic Test - Diabetes
Diagnostic Test - Diabetes Product Overview
Diagnostic Test - Group B Streptococcus
Diagnostic Test - Group B Streptococcus Product Overview
Diagnostic Test - Kidney Disease
Diagnostic Test - Kidney Disease Product Overview
Diagnostic Test - Prostate Cancer
Diagnostic Test - Prostate Cancer Product Overview
Diagnostic Test - Sepsis
Diagnostic Test - Sepsis Product Overview
Diagnostic Test - Staphylococcus aureus
Diagnostic Test - Staphylococcus aureus Product Overview
Rapid Diagnostic Test - Vitamin D
Rapid Diagnostic Test - Vitamin D Product Overview
Ultibro Breezhaler
Ultibro Breezhaler Product Overview
Novartis AG - Key Competitors
Novartis AG - Key Employees
Novartis AG - Key Employee Biographies
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Novartis AG, Recent Developments
Apr 24, 2014: Novartis delivered solid sales and profit growth in the first quarter of 2014; strong innovation reinforces growth prospects as company transforms portfolio
Apr 22, 2014: Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics
Apr 09, 2014: Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
Apr 03, 2014: Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
Feb 27, 2014: NVISION Laser Eye Centers Now Provides the Fastest LASIK Surgery Available in the U.S. With the WaveLight EX500 Laser
Feb 26, 2014: Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation
Feb 25, 2014: Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Feb 19, 2014: MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trials
Feb 03, 2014: Novartis To Reduce Or Transfer Approximately 4,000 Jobs
Jan 29, 2014: Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects

Companies Mentioned:

Novartis AG (NOVN)